Durable response to combination immunotherapy using Nivolumab and Ipilimumab in metastatic succinate dehydrogenase (SDH)- deficient gastrointestinal stroma tumour

The introduction of targeted therapy using c-kit and multityrosine kinase inhibitors has led to dramatic improvement in the outcome of patients with advanced gastrointestinal stroma tumours (GIST) over the last two decades [1]. Approximately 10% of GISTs are succinate dehydrogenase (SDH)- deficient either due to a germline or somatic mutation in the SDHA/B/C/D genes, or due to SDHC promotor methylation. The SDH-deficient GIST subgroup is associated with particular demographic features (younger age, female gender, stomach being primary tumour site) [2,3].

Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: O. Klein, J. Palmer, A. Behren, J. Cebon, D. Kee Tags: Letter Source Type: research